Matrix metalloproteinases and inhibitors in cartilage tissue engineering

Journal of Tissue Engineering and Regenerative Medicine

Volumn 6, Issue 2, 2012, Pages 144-154

  Li, Hanwei ^a   Feng, Felicia ^a   Bingham, Clifton O ^b   Elisseeff, Jennifer H ^a  

^a Johns Hopkins University School of Medicine   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chondrocytes; Extracellular matrix; Inhibitors; Matrix metalloproteinases; Mesenchymal stem cells; Osteoarthritis

Indexed keywords

BLOOD VESSELS; BONE; CARTILAGE; CELL ENGINEERING; ENZYME ACTIVITY; ENZYME INHIBITION; PATIENT TREATMENT; POLYETHYLENE GLYCOLS; STEM CELLS; TISSUE ENGINEERING; TUMORS;

CARTILAGE TISSUE ENGINEERING; CHONDROCYTES; EXTRACELLULAR MATRICES; INHIBITOR; MATRIX; MATRIX METALLOPROTEINASE; MESENCHYMAL STEM CELL; METALLOPROTEINASE ACTIVITY; METALLOPROTEINASES; OSTEOARTHRITIS;

CELL CULTURE;

AGGRECAN; BETA ACTIN; BONE SIALOPROTEIN; COLLAGEN TYPE 2; GLYCOSAMINOGLYCAN; GROWTH FACTOR; MACROGOL; MATRIX METALLOPROTEINASE; OSTEOPONTIN;

ARTICLE; BIOCHEMICAL COMPOSITION; CARTILAGE CELL; CELL ENCAPSULATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HISTOLOGY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MESENCHYMAL STEM CELL; OSTEOARTHRITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA EXTRACTION; TISSUE ENGINEERING; UPREGULATION; ZYMOGRAPHY;

EID: 84856298526     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.408     Document Type: Article

References (45)

1. Balbin M, Fueyo A, Knauper V, et al. 2001; Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J Biol Chem 276: 10253-10262.
2. Baragi VM, Becher G, Bendele AM, et al. 2009; A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 60: 2008-2018.
3. Bertram H, Boeuf S, Wachters J, et al. 2009; Matrix metalloprotease inhibitors suppress initiation and progression of chondrogenic differentiation of mesenchymal stromal cells in vitro. Stem Cells Dev 18: 881-892.
4. Bramono DS, Richmond JC, Weitzel PP, et al. 2004; Matrix metalloproteinases and their clinical applications in orthopaedics. Clin Orthop Relat Res 428: 272-285.
5. Chun TH, Hotary KB, Sabeh F, et al. 2006; A pericellular collagenase directs the three-dimensional development of white adipose tissue. Cell 125: 577-591.
6. Clark IM, Parker AE. 2003; Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets 7: 19-34.
7. Connelly JT, Wilson CG, Levenston ME. 2008; Characterization of proteoglycan production and processing by chondrocytes and BMSCs in tissue engineered constructs. Osteoarthr Cartilage 16: 1092-1100.
8. Coussens LM, Fingleton B, Matrisian LM. 2002; Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392.
9. D'Angelo M, Yan Z, Nooreyazdan M, et al. 2000; MMP-13 is induced during chondrocyte hypertrophy. J Cell Biochem 77: 678-693.
10. Felson DT, Neogi T. 2004; Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum 50: 341-344.
11. Freed LE, Langer R, Martin I, et al. 1997; Tissue engineering of cartilage in space. Proc Natl Acad Sci USA 94: 13885-13890.
12. Goldring MB. 2000; The role of the chondrocyte in osteoarthritis. Arthritis Rheum 43: 1916-1926.
13. Goldring MB, Goldring SR. 2007; Osteoarthritis. J Cell Physiol 213: 626-634.
14. Goldring SR, Goldring MB. 2004; The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 427:(suppl): S27-36.
15. Hayami T, Pickarski M, Zhuo Y, et al. 2006; Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 38: 234-243.
16. Hoekstra R, Eskens FA, Verweij J. 2001; Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 6: 415-427.
17. Hsieh YS, Yang SF, Chu SC, et al. 2004; Expression changes of gelatinases in human osteoarthritic knees and arthroscopic debridement. Arthroscopy 20: 482-488.
18. Johnson LL, Dyer R, Hupe DJ. 1998; Matrix metalloproteinases. Curr Opin Chem Biol 2: 466-471.
19. Johnstone B, Hering TM, Caplan AI, et al. 1998; In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res 238: 265-272.
20. Karsdal MA, Madsen SH, Christiansen C, et al. 2008; Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther 10: R63.
21. Kijowski R, Blankenbaker D, Stanton P, et al. 2006; Correlation between radiographic findings of osteoarthritis and arthroscopic findings of articular cartilage degeneration within the patellofemoral joint. Skeltal Radiol 35: 895-902.
22. Kim IS, Otto F, Zabel B, et al. 1999; Regulation of chondrocyte differentiation by Cbfa1. Mech Dev 80: 159-170.
23. Kim TK, Sharma B, Williams CG, et al. 2003; Experimental model for cartilage tissue engineering to regenerate the zonal organization of articular cartilage. Osteoarthr Cartilage 11: 653-664.
24. Kinoh H, Sato H, Tsunezuka Y, et al. 1996; MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci 109: 953-959.
25. Krzeski P, Buckland-Wright C, Balint G, et al. 2007; Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 9: R109.
26. Leff RL, Elias I, Ionescu M, et al. 2003; Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. J Rheumatol 30: 544-549.
27. Lin PM, Chen CT, Torzilli PA. 2004; Increased stromelysin-1 (MMP-3), proteoglycan degradation (3B3 and 7D4) and collagen damage in cyclically load-injured articular cartilage. Osteoarthr Cartilage 12: 485-496.
28. -ΔΔCT) method. Methods 25: 402-408.
29. Mitchell PG, Magna HA, Reeves LM, et al. 1996; Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 97: 761-768.
30. Murphy G, Knauper V, Atkinson S, et al. 2002; Matrix metalloproteinases in arthritic disease. Arthritis Res 4(suppl 3): S39-49.
31. Murphy G, Nagase H. 2008; Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 4: 128-135.
32. Neuhold LA, Killar L, Zhao W, et al. 2001; Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest 107: 35-44.
33. Petersson IF, Boegard T, Svensson B, et al. 1998; Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint. Br J Rheumatol 37: 46-50.
34. Pullig O, Weseloh G, Gauer S, et al. 2000; Osteopontin is expressed by adult human osteoarthritic chondrocytes: protein and mRNA analysis of normal and osteoarthritic cartilage. Matrix Biol 19: 245-255.
35. Renkiewicz R, Qiu L, Lesch C, et al. 2003; Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 48: 1742-1749.
36. Rogers J, Shepstone L, Dieppe P. 2004; Is osteoarthritis a systemic disorder of bone? Arthritis Rheum 50: 452-457.
37. Salaffi F, Carotti M, Stancati A, et al. 2003; Radiographic assessment of osteoarthritis: analysis of disease progression. Aging Clin Exp Res 15: 391-404.
38. Scharstuhl A, Glansbeek HL, van Beuningen HM, et al. 2002; Inhibition of endogenous TGF-β during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. J Immunol 169: 507-514.
39. Sharma B, Williams CG, Khan M, et al. 2007; In vivo chondrogenesis of mesenchymal stem cells in a photopolymerized hydrogel. Plast Reconstr Surg 119: 112-120.
40. Shingleton WD, Hodges DJ, Brick P, et al. 1996; Collagenase: a key enzyme in collagen turnover. Biochem Cell Biol 74: 759-775.
41. Sparano JA, Bernardo P, Stephenson P, et al. 2004; Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 22: 4683-4690.
42. Tallheden T, Bengtsson C, Brantsing C, et al. 2005; Proliferation and differentiation potential of chondrocytes from osteoarthritic patients. Arthritis Res Ther 7: R560-568.
43. Ulrich-Vinther M, Maloney MD, Schwarz EM, et al. 2003; Articular cartilage biology. J Am Acad Orthop Surg 11: 421-430.
44. Visse R, Nagase H. 2003; Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839.
45. Williams CG, Kim TK, Taboas A, et al. 2003; In vitro chondrogenesis of bone marrow-derived mesenchymal stem cells in a photopolymerizing hydrogel. Tissue Eng 9: 679-688.